KelSie Biotech develops high-bioavailability delivery methods for active pharmaceutical ingredients across medical, nutraceutical and CBD/cannabis fields. The company licenses patented and proprietary technologies based on novel particle morphology science. Its technology portfolio includes dry-inhaled powder and true sublingual delivery systems. The dry-inhaled powder technology completed Phase I clinical trials for delivery of a stable measles vaccine. Led by Cameron Keluche and based in Boulder, CO, KelSie pursues a licensing business model for its delivery platforms. The company said it will use newly raised funds to support scientific research and market expansion.

Total raised

$5M

Funding rounds

1

Latest round

Series A

Latest activity

May 2019